A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Overview

The purpose of this study is to find molecular signs (biomarkers) to better understand the role of green tea as an anti-cancer and anti-inflammation agent in women with newly-diagnosed ductal carcinoma in situ (DCIS).

Full Title of Study: “A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2015

Detailed Description

Many studies have shown that green tea may have anti-cancer and anti-inflammatory effects in cancer cells and animal models of breast cancer. Some studies have found that Asian women who drink many cups of green tea have lower rates of breast cancer. Green tea may have an effect on proliferative and inflammatory pathways. Women with ductal carcinoma in situ (DCIS) have been found to have inflammation in the breast tissue surrounding DCIS lesions. Inflammatory pathways are being studied for a possible link to cancer. This study is designed to evaluate changes in biomarkers of proliferation, inflammation, and angiogenesis in response to green tea intake.

Interventions

  • Drug: Polyphenon E
    • three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery

Arms, Groups and Cohorts

  • Experimental: Women with Ductal Carcinoma in Situ
    • Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E

Clinical Trial Outcome Measures

Primary Measures

  • Percent Change in K167 Staining
    • Time Frame: Prior to starting study and after 4-6 weeks of treatment

Secondary Measures

  • Decrease in MRI Volume and Signal Enhancement Ratio (SER) of the Breast Lesion From Pre- to Post-treatment.
    • Time Frame: Prior to study start and 4-6 weeks after treatment
  • Change in Percent Staining of CD68 in Breast Tissue
    • Time Frame: Prior to study start and 4-6 weeks after treatment
  • Change in Percent Staining of CD31 in Breast Tissue
    • Time Frame: Prior to study start and 4-6 weeks after treatment
  • Change in Percent Staining of VEGF in Breast Tissue
    • Time Frame: Prior to study start and after 4-6 weeks of treatment
  • Change in Serum Levels of IGF-1
    • Time Frame: Prior to study start and after 4-6 weeks of treatment
  • Safety of Green Tea Ingestion
    • Time Frame: 6 weeks
    • Number of patients with adverse event.

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on breast MRI of at least 1-cm3 in volume. – Patients may have undergone treatment with prior chemotherapy if this was greater than 12 months prior to current diagnosis. – Age >18 years. – ECOG performance status <2 (Karnofsky >60%) – Life expectancy of greater than 12 months. – Normal organ and marrow function as defined below: – leukocytes >3,000/mcL – absolute neutrophil count >1,500/mcL – platelets >100,000/mcL – total bilirubin within normal institutional limits – AST(SGOT) & ALT(SGPT)within normal institutional limits – creatinine <1.5 times institutional upper limit of normal or creatinine clearance >60 mL/min/1.73 m2 – Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:

  • Pregnancy – Patients who have undergone prior excisional biopsy for DCIS. – Patients who are unable to undergo MRI due to claustrophobia or other reason. – Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this study. – Patients receiving any other chemotherapy or investigational agents. – History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extracts or sensitivity to green tea. – Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Chicago
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nora Jaskowiak, MD, Principal Investigator, University of Chicago

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.